Clinical Trial Results:
Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an α-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients.
A 5 to 8 months, national, multicentre, open study.
Efficacité et tolérance du gliclazide LM (30 à 120 mg/j per os) associé ou non à la metformine ou à un inhibiteur des α-glucosidases pendant le jeûne du Ramadan chez des patients diabétiques de type 2.
Etude nationale, multicentrique de 5 à 8 mois de traitement en ouvert.
Summary
|
|
EudraCT number |
2006-006754-10 |
Trial protocol |
FR |
Global completion date |
13 May 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 Sep 2017
|
First version publication date |
20 Sep 2017
|
Other versions |
|
Summary report(s) |
Statement_CL3-05702-014 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.